Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients

Journal of Clinical Psychopharmacology

Volumn 29, Issue 1, 2009, Pages 77-81

  Elkader, Alexander K ^a   Brands, Bruna ^a,b   Dunn, Edward ^c   Selby, Peter ^a,d   Sproule, Beth Ann ^a,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b HEALTH CANADA   (Canada)

^c DYNACARE LABORATORIES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

(S) methadone; Major depressive disorder; Methadone maintenance treatment; Opioid withdrawal; Pharmacokinetics pharmacodynamics

Indexed keywords

METHADONE; NARCOTIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DYSPHORIA; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MAXIMUM PLASMA CONCENTRATION; METHADONE TREATMENT; MOOD; OPIATE ADDICTION; PATIENT SATISFACTION; PHARMACODYNAMICS; PRIORITY JOURNAL; RATING SCALE; SUBJECTIVE OPIOID WITHDRAWAL SCALE; TREATMENT RESPONSE; COMPARATIVE STUDY; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL ASPECT; WITHDRAWAL SYNDROME;

ADULT; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; MALE; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; PATIENT SATISFACTION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 62649138791     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318192eb00     Document Type: Article

References (29)

1. Office of National Drug Control Policy. The economic costs of drug abuse in the United States, 1992-1998. Washington, DC: Executive Office of the President (Publication No. NCJ-190636); 2001.
2. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264(19):2511-2518.
3. Dole VP, Nyswander MA. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965;193:646-650.
4. Dyer KR, White JM. Patterns of symptom complaints in methadone maintenance patients. Addiction. 1997;92(11):1445-1455.
5. Dyer KR, Foster DJ, White JM, et al. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther. 1999;65(6):685-694.
6. Isbell H, Eisenman AJ. The addiction liability of some drugs of the methadone series. J Pharmacol Exp Ther. 1948;93:305-313.
7. Fraser HF, Isbell H. Human pharmacology and addictiveness of certain dextroisomers of synthetic analgesics. Bull Narc. 1962;14:25-35.
8. Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med. 1966;66:2011-2017.
9. Judson BA, Horns WH, Goldstein MD. Side effects of levomethadone and racemic methadone in a maintenance program. Clin Pharmacol Ther. 1976;20(4):445-449.
10. Olsen GD, Wendel HA, Livermore JD, et al. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther. 1977;21(2):147-157.
11. Dole VP. Implication of methadone maintenance for theories of narcotic addiction. JAMA. 1988;260:80-84.
12. Mitchell TB, Dyer KR, Newcombe D, et al. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. Br J Clin Pharmacol. 2004;58(6):609-617.
13. Foster DJ, Somogyi AA, Dyer KR, et al. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000;50(5):427-440.
14. Dyer KR, White J, Foster DJR, et al. The relationship between mood state and plasma methadone concentration in maintenance patients. J Clin Psychopharmacol. 2001;21(1):78-84.
15. McNair DM, Lorr M, Droppleman LF. Profile of Mood States Manual. San Diego, CA: Educational and Industrial Testing Service; 1981.
16. Woody GE, Luborsky L, McLellan AT, et al. Psychotherapy for opiate addicts. Does it help? Arch Gen Psychiatry. 1983;40(6):639-645.
17. Mason BJ, Kocsis JH, Melia D, et al. Psychiatric comorbidity in methadone maintained patients. J Addict Dis. 1998;17(3):75-89.
18. Teesson M, Havard A, Fairbairn S, et al. Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend. 2005;78:309-315.
19. Cole JO, Orzack MH, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry. 1982;43(12):69-74.
20. Haertzen CA, Hill HE, Belleville RE. Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia. 1963;4:155-166.
21. Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245-258.
22. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293-308.
23. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
24. Rounsaville BJ, Weissman MM, Crists-Christoph K, et al. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39(2):151-156.
25. Hatsukami D, Pickens RW. Posttreatment depression in an alcohol and drug abuse population. Am J Psychiatry. 1982;139:1563-1566.
26. Compton WM, Cottler LB, Jacobs JL, et al. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry. 2003;160:890-895.
27. Havard A, Teesson M, Darke S, et al. Depression among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat. 2006;30:355-362.
28. Brienza RS, Stein MD, Chen M, et al. Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat. 2000;18:331-337.
29. Schreiber S, Peles E, Adelson M. Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropic medication use in methadone maintenance treatment (MMT) patients. Drug Alcohol Depend. 2008;92(1-3):79-85.